Phase II checkpoint inhibitor combination study of SCIB1 in melanoma patients
Phase of Trial: Phase II
Latest Information Update: 11 Jul 2017
At a glance
- Drugs Checkpoint kinase inhibitors (Primary) ; SCIB 1 (Primary)
- Indications Malignant melanoma
- Focus Therapeutic Use
- 11 Jul 2017 According to Scancell media release, the company is on track to submit the IND for this study in 3Q17.
- 16 Sep 2016 According to Scancell media release, enrolment expected to commence in Q3 2017.
- 16 Sep 2016 Planned initiation date changed from 1 Jan 2017 to 1 Jul 2017, as per Scancell media release.